down arrow

Alaunos Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98973P1012
USD
3.59
0.31 (9.45%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.463.69

52 Week

1.316.20
Valuation
Technical
Day's Volume

CASH

28.89 k

Shareholding (Mar 2025)

FII

1.87%

Held by 15 FIIs

DII

93.9%

Held by 4 DIIs

Promoter

0.00%

How big is Alaunos Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Alaunos Therapeutics, Inc. has a market capitalization of 6.00 million, with net sales of 0.00 million and a net profit of -4.07 million over the latest four quarters. The company reported shareholder's funds of 2.06 million and total assets of 2.75 million as of Dec 24.

Market Cap: As of Jun 18, Alaunos Therapeutics, Inc. has a market capitalization of 6.00 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Alaunos Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -4.07 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 2.06 million and total assets of 2.75 million.

Read More

What does Alaunos Therapeutics, Inc. do?

22-Jun-2025

Alaunos Therapeutics, Inc. is a micro-cap biopharmaceutical company focused on developing cancer therapies in the immuno-oncology sector. As of March 2025, it reported net sales of $0 million and a net loss of $1 million, with a market cap of $6 million.

Overview:<BR>Alaunos Therapeutics, Inc. is a biopharmaceutical company focused on developing cancer therapies in the immuno-oncology sector, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 6.00 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.30 <BR>Return on Equity: -384.78% <BR>Price to Book: 5.67<BR><BR>Contact Details:<BR>Address: One First Avenue Parris Building 34 Navy Yard Plaza BOSTON MA : 02129 <BR>Tel: ['1 617 2591970', '1 617 5021881'] <BR>Fax: 1 617 2412855 <BR>Website: http://www.ziopharm.com/

Read More

Who are in the management team of Alaunos Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Alaunos Therapeutics, Inc. includes Chairman James Huang, CEO Dr. Laurence Cooper, Lead Independent Director Heidi Hagen, and Directors J. Kevin Buchi, Jaime Vieser, Holger Weis, and Independent Director Dr. Christopher Bowden. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Alaunos Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. James Huang, Chairman of the Board<BR>- Dr. Laurence Cooper, Chief Executive Officer and Director<BR>- Ms. Heidi Hagen, Lead Independent Director<BR>- Mr. J. Kevin Buchi, Director<BR>- Mr. Jaime Vieser, Director<BR>- Mr. Holger Weis, Director<BR>- Dr. Christopher Bowden, Independent Director<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Alaunos Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 14, 2023, Alaunos Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to significant negative financial ratios, including a Price to Book Value of 4.70 and a ROCE of -416.30%, despite a recent stock price surge.

As of 14 November 2023, Alaunos Therapeutics, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued, given its significant negative financial ratios, including a Price to Book Value of 4.70 and an EV to EBITDA of -1.12. The return on capital employed (ROCE) is alarmingly low at -416.30%, indicating severe operational inefficiencies.<BR><BR>In comparison to its peers, Alaunos Therapeutics has a worse EV to EBITDA ratio than MAIA Biotechnology, Inc. at -2.1328 and MiNK Therapeutics, Inc. at -3.4718, both of which also do not qualify for a positive valuation. Despite a recent surge in stock price with a 1-month return of 68.42%, the overall financial health and valuation metrics suggest that the company remains overvalued in the current market landscape.

Read More

Is Alaunos Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Alaunos Therapeutics, Inc. shows a mildly bullish trend based on daily moving averages and monthly MACD, but mixed signals from weekly indicators and significant long-term underperformance compared to the S&P 500 suggest caution.

As of 8 September 2025, the technical trend for Alaunos Therapeutics, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the monthly MACD is also mildly bullish. However, the weekly MACD and KST are bearish, and the Bollinger Bands show a mildly bearish trend in both weekly and monthly perspectives. The Dow Theory indicates a mildly bullish trend on the weekly timeframe. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 3.36% and 5.58%, respectively, compared to the S&P 500's 1.05% and 2.33%. However, over the longer term, the stock has significantly underperformed the benchmark, with a 1-year return of -21.15% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from various indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.79

stock-summary
Return on Equity

-108.22%

stock-summary
Price to Book

1.32

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
60.27%
0%
60.27%
6 Months
28.67%
0%
28.67%
1 Year
48.35%
0%
48.35%
2 Years
-65.31%
0%
-65.31%
3 Years
-96.48%
0%
-96.48%
4 Years
-98.04%
0%
-98.04%
5 Years
-99.13%
0%
-99.13%

Alaunos Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Alaunos Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Alaunos Therapeutics, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the monthly MACD is also mildly bullish. However, the weekly MACD and KST are bearish, and the Bollinger Bands show a mildly bearish trend in both weekly and monthly perspectives. The Dow Theory indicates a mildly bullish trend on the weekly timeframe. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 3.36% and 5.58%, respectively, compared to the S&P 500's 1.05% and 2.33%. However, over the longer term, the stock has significantly underperformed the benchmark, with a 1-year return of -21.15% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from various indicators....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.20%
EBIT Growth (5y)
14.17%
EBIT to Interest (avg)
-35.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.16%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.70
EV to EBIT
-1.12
EV to EBITDA
-1.12
EV to Capital Employed
4.65
EV to Sales
4.65
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-416.30%
ROE (Latest)
-384.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 9 Schemes (4.22%)

Foreign Institutions

Held by 15 Foreign Institutions (1.87%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -57.14% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.00",
          "val2": "-1.10",
          "chgp": "9.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.10",
          "val2": "-1.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-546,000.00%",
          "chgp": "54,600.00%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 86.61% vs 6.90% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.80",
          "val2": "-26.20",
          "chgp": "81.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.90",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-5.80",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.70",
          "val2": "-35.10",
          "chgp": "86.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-481,200.00%",
          "val2": "-5,698,600.00%",
          "chgp": "5,21,740.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.00
-1.10
9.09%
Interest
0.00
0.00
Exceptional Items
-0.00
0.00
Consolidate Net Profit
-1.10
-1.10
Operating Profit Margin (Excl OI)
0.00%
-546,000.00%
54,600.00%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -57.14% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.80
-26.20
81.68%
Interest
0.00
1.90
-100.00%
Exceptional Items
0.00
-5.80
100.00%
Consolidate Net Profit
-4.70
-35.10
86.61%
Operating Profit Margin (Excl OI)
-481,200.00%
-5,698,600.00%
5,21,740.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 86.61% vs 6.90% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Alaunos Therapeutics, Inc. stock-summary
stock-summary
Alaunos Therapeutics, Inc.
Pharmaceuticals & Biotechnology
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
Company Coordinates stock-summary
Company Details
One First Avenue Parris Building 34 Navy Yard Plaza BOSTON MA : 02129
stock-summary
Tel: 1 617 25919701 617 5021881
stock-summary
http://www.ziopharm.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."